Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 - Test2 - elhamkhani - TriplyDB

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

http://www.wikidata.org/entity/Q24624887

about

Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis EMT and interstitial lung disease: a mysterious relationship The water network in galectin-3 ligand binding site guides inhibitor design Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition Epithelial-mesenchymal transition: An emerging target in tissue fibrosis Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease Promising therapies for treatment of nonalcoholic steatohepatitis.Cell Intrinsic Galectin-3 Attenuates Neutrophil ROS-Dependent Killing of Candida by Modulating CR3 Downstream Syk Activation.Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy.Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis.Glycobiology of ocular angiogenesis.Two clinical phenotypes in polycythemia vera.The role of Galectin-3 in α-synuclein-induced microglial activation.Fingerprinting of galectins in normal, P. aeruginosa-infected, and chemically burned mouse corneas Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis.Therapy of experimental NASH and fibrosis with galectin inhibitors.The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists Regulation of ozone-induced lung inflammation and injury by the β-galactoside-binding lectin galectin-3.Differential development of oil granulomas induced by pristane injection in galectin-3 deficient mice The roles of connective tissue growth factor in the development of anastomotic esophageal strictures.Chitinase 3-like-1 and its receptors in Hermansky-Pudlak syndrome-associated lung disease.Galectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal Damage Perdeuteration, crystallization, data collection and comparison of five neutron diffraction data sets of complexes of human galectin-3C Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis.Hypoxia-inducible factor prolyl-hydroxylase-2 mediates transforming growth factor beta 1-induced epithelial-mesenchymal transition in renal tubular cells.Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors.Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities.Acute exacerbations in patients with idiopathic pulmonary fibrosis.Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis.Update in diffuse parenchymal lung disease 2012.Emerging therapeutic interventions for idiopathic pulmonary fibrosis.Galectin-3: an emerging all-out player in metabolic disorders and their complications.Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis.Long-term sequelae from acute kidney injury: potential mechanisms for the observed poor renal outcomes.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease.

P2860

Q26771826-6052D098-CA7A-432A-AE2F-A5E7F4CFBB00 Q26779846-37717934-5F0F-4A5F-99A0-B7B4F5CBAAAF Q26824760-B6495E86-01B2-4F7D-B659-401E861B46DE Q27697923-0BCE3808-12DD-4DEB-B768-2165B7307CEA Q27714964-172FEC68-B128-4E43-B9CA-F5CBE434F45A Q28083351-8E2A8FFC-ACC3-4D1E-BB95-BAA6722DC7FF Q28534290-AB6EED6A-EC49-44B3-B5D3-C3CB3CBADC36 Q30248578-4166D587-E85C-47E2-B5B7-B555EF0AD29D Q30837287-4AF5FDDB-AFBD-45AB-A8CF-0B8ECB3583B4 Q30841381-F96AD83C-8CB8-4E3B-9DBC-E728CA0B44A7 Q33799623-5B8C486C-5ED6-443F-AA8E-587BAF874805 Q34414227-D7440DF8-3662-4926-9B5F-F9580320C9FF Q34415448-C0EFC851-DAF6-458B-B4F8-BFA503454E6F Q34537231-CB27CDBA-2BE3-49F7-A0C2-B6C8C52BB216 Q34999835-7521A8B8-77CB-4102-974E-E78791A7F17E Q35070734-5DD70D59-DC9C-45E2-AD30-8E575E03CF9A Q35075568-C38829AB-AE53-47E5-94C1-5CC76F69F9D2 Q35191679-8EC82D69-5295-4DA0-A35E-AC82EE90C35F Q35533394-B83779B8-5E8B-4643-943A-519AEC674348 Q35842426-C509EB81-7FE5-4663-A5DC-B8B54215D39F Q35992091-0F6F6787-CE87-4299-87AE-9A9A58B22919 Q36040475-2E2664A2-5A0E-4DB9-83EF-3EEFFB1DEDAC Q36187612-A5968606-DB28-4633-B3A2-1FB2DC3B2004 Q36191511-0EDE722D-A4FD-4FEC-B48F-4A68853C8F4A Q36538945-62D2710E-C796-4634-8F69-D7E690793D17 Q36780416-238E70DC-1D98-4B90-911E-ADB44E7F7DAB Q36885706-3FD65AE6-9023-4395-ACCA-ABA626E716C3 Q37065931-A871B24E-B466-4F86-A540-09522725D2AE Q37096426-16A09A06-295C-4A3A-8985-C91E2EF4A27A Q37125501-0F82C4DE-B385-4258-B781-88AD02E1C66A Q37152742-DC9D0A9E-B8FE-443A-9F00-D63C7BA4583E Q37164851-7CE2F19B-19E8-4825-BF8E-2CE16FF0955D Q37579627-DFF45879-0BF6-44F4-A00B-6B704DFF9322 Q38103298-D6DB6487-0C88-424D-90D8-54D76EFA5AF1 Q38207153-3F230D22-70EB-49D7-A4A3-B84B55758C96 Q38258947-72DD2BF7-A30E-4985-8875-BEE52295A76A Q38364228-D64B5CF8-E336-4C2C-A3CC-2B73B36B3FD3 Q38426618-AE7AD89F-6EE4-45AE-BD76-F50A904F993D Q38580461-AC938E31-6076-4741-9B85-9456EED06E37 Q38642870-68AC7948-40E8-410E-9400-62C69B4BABAF

P2860

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

http://www.wikidata.org/entity/Q24624887

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@ast

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@en

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@nl

type

label

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@ast

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@en

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@nl

prefLabel

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@ast

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@en

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@nl

P1433

Q24624887-85A3E6E1-4834-42CA-B30B-30D308047341

P1476

Q24624887-91AC6B1A-143C-4C5E-9303-2343A3AF0D99

P2093

Q24624887-2FC0A509-DB36-4A05-86E8-D300B4A14803

Q24624887-5138C065-FB2E-441C-B58A-04E9001AD890

Q24624887-B5DFEC37-79EA-4837-96D1-C2C5350024D6

Q24624887-BAE70B33-74AD-4B4C-A224-E0695EEC3DBE

Q24624887-DEC86531-A5EF-4550-B4D1-79F1B2A82169

Q24624887-EBAB79E4-3629-41C2-8F9E-5178B423CE9B

Q24624887-FC9CB757-E050-4884-97F9-816585157627

Q24624887-FF3BDA9A-409C-40EE-895C-8E7B66195DC8

P2860

Q24624887-001458A8-F00D-4E36-896C-89843F766C4D

Q24624887-0350AE1B-5F7A-4EB2-BE8F-0A2560292C9A

Q24624887-07DE75D3-963A-48C9-BD53-0886A474E14B

Q24624887-0B60DA4F-26AF-411B-A4CD-4CB469E6E80D

Q24624887-15032DA1-3D47-4FEF-B2AA-90501B3C4B4F

Q24624887-1734B125-0493-4348-9588-FA9630EC522F

Q24624887-18ECB393-03D0-4B4E-80E3-21D705ACFD93

Q24624887-1D024E45-FA7C-4063-BC06-6F29397259BB

Q24624887-29E882D9-8203-4ACD-99F7-957A1F144986

Q24624887-30C6B7BD-5665-42EB-BFF3-38B730522158

P304

Q24624887-75D3DB21-A42E-4FF1-9BB2-C13154E90A57

P31

Q24624887-6CC9F5BD-DBC3-48CD-9119-7C3EE8B2F117

P3181

Q24624887-4F47052F-D70E-44F3-968C-B211E290C954

P356

Q24624887-ABBF328F-FC31-4ED4-9EC4-69A924C548FB

P407

Q24624887-B2B04112-5CB1-4FD2-9D39-E9093D25C02D

P433

Q24624887-010031CE-ACC5-4012-99C3-D1AAAECA2417

P478

Q24624887-23EFB40B-F962-4277-973C-0D0847107BF3

P50

Q24624887-2F4BDCEB-6FAB-4908-A1AE-5A8048FD50AE

Q24624887-36362382-0515-42C6-B26E-193B3FDDCA5F

Q24624887-7A5543FC-A21D-475A-9DDF-8AE70503891E

P577

Q24624887-79AEA35F-6BD7-45E6-B74E-CC5C9829AAD0

P5875

Q24624887-611D62BE-649D-414A-917C-B5D3D59C4F23

P698

Q24624887-DA3F0AEC-8905-487D-AC20-731024A85B19

P921

Q24624887-59D79447-AEA5-483F-82A2-074C92391D68

P932

Q24624887-1B0117FD-2122-459B-A5C5-A33A9B4E9439

P3181

P356

RCCM.201106-0965OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3

@en

P2093

A John Simpson

http://www.w3.org/2001/XMLSchema#string

Alison C Mackinnon

http://www.w3.org/2001/XMLSchema#string

Jack Gauldie

http://www.w3.org/2001/XMLSchema#string

Michael A Gibbons

http://www.w3.org/2001/XMLSchema#string

Nik Hirani

http://www.w3.org/2001/XMLSchema#string

Sarah L Farnworth

http://www.w3.org/2001/XMLSchema#string

Tamara Delaine

http://www.w3.org/2001/XMLSchema#string

Tariq Sethi

http://www.w3.org/2001/XMLSchema#string

P2860

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis

Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder

TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT)

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix

TGF-beta-induced epithelial to mesenchymal transition

Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease.

Factors associated with the use of corticosteroids in the initial management of idiopathic pulmonary fibrosis

Incidence and prevalence of idiopathic pulmonary fibrosis.

P304

537-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2079802

http://www.w3.org/2001/XMLSchema#string

P356

10.1164/RCCM.201106-0965OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

185

http://www.w3.org/2001/XMLSchema#string

P50

Stuart J Forbes

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51807741

http://www.w3.org/2001/XMLSchema#string

P698

22095546

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis

P932

3410728

http://www.w3.org/2001/XMLSchema#string